The overall goal of this grant proposal entitled "Regulation of Lysosomal cholesterol in Atherosclerosis" is to define a novel role of CD38-NAADP pathway in the regulation of lysosomal cholesterol transport in macrophages in atherogenesis. The hypothesis being tested is that a fine regulatory mechanism of lysosome function via CD38-NAADP signaling pathway plays a critical role in removal of free cholesterol from lysosomes in macrophages and that the abnormality of such CD38-associated lysosome regulation contributes to the pathogenesis of atherosclerosis.
Three specific aims to be determined are: 1) To determine whether the deficiency of CD38-NAADP signaling pathway contributes to the accumulation of lysosomal free cholesterol and foam cell formation and to explore the underlying mechanisms using primary cultures of macrophages prepared from CD38-/- and wild type(WT) mice~ 2) To determine whether the deficiency in CD38-NAADP signaling pathway in macrophages leads to lysosomal free cholesterol deposition and consequent atherosclerosis in coronary arteries and aorta using bone marrow transplantation model within CD38-/-,TRP- ML1-/- (transient receptor potential-mucolipin 1) and WT mice~ and 3) To examine how the deficiency of CD38 with deranged lysosomes induces dysfunction of macrophages and atherosclerosis and to define the mechanism mediating the actions of accumulated lysosomal free cholesterol in atherosclerosis by transplanting CD38-/- bone marrow into LDLr-/- mice. The findings of this grant proposal will, for the first time link a membrane differentiation antigen - CD38 to the regulation of lysosome function n free cholesterol clearance through its product, NAADP, which as a second messenger regulates lysosome calcium movement. It is predicted that these proposed studies, when completed, will reveal a new molecular signaling pathway contributing to the pathogenesis of atherosclerosis and thereby direct toward the development of new therapeutic strategies for the prevention and treatment of atherosclerosis. Such direct therapeutic manipulation of the CD38-NAADP signaling pathway in regulating lysosomal cholesterol metabolism and transport may pinpoint the atherosclerotic lesions to reverse foam cell formation, which could be more effective in the prevention and treatment of atherosclerosis, compared to current systemic lipid-lowering medications.

Public Health Relevance

The pathological hallmark of atherosclerosis is the excessive accumulation of lipids in lysosomes of macrophages and that a majority of the lipids in the lipid-swollen lysosomes is cholesterol in both the free and esterified form, which leads to their transformation into foam cells. The research goal of this grant proposal entitled "Regulation of Lysosomal cholesterol in Atherosclerosis" is to define a novel role of CD38-NAADP pathway in the regulation of lysosomal cholesterol transport in macrophages in atherogenesis. It is predicted that these proposed studies, when completed, may direct toward the development of new therapeutic strategies for the prevention and treatment of atherosclerosis, by pinpointing the atherosclerotic lesions to reverse foam cell formation, which could be more effective in the prevention and treatment of atherosclerosis, compared to current systemic lipid-lowering medications.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
1R01HL115068-01
Application #
8345838
Study Section
Atherosclerosis and Inflammation of the Cardiovascular System Study Section (AICS)
Program Officer
Olive, Michelle
Project Start
2012-07-13
Project End
2017-06-30
Budget Start
2012-07-13
Budget End
2013-06-30
Support Year
1
Fiscal Year
2012
Total Cost
$336,375
Indirect Cost
$111,375
Name
Virginia Commonwealth University
Department
Pharmacology
Type
Schools of Medicine
DUNS #
105300446
City
Richmond
State
VA
Country
United States
Zip Code
23298